The analysis of Disease-Free Survival (DFS) indicated that higher levels of PROX1 and α-SMA were correlated with increased recurrence rates, highlighting their potential as prognostic markers and might be key therapeutic targets for CRC. The gene discussed is ACTA1; the disease is colorectal carcinoma.